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The lung disease cystic fibrosis (CF) has
the dubious distinction of being the most
common fatal recessive hereditary illness
among people of Northern European
descent. Most patients die of respiratory
failure because their lungs are not ade-
quately protected from airborne bacteria
and other pathogens. In healthy people,
cells lining the airways ward off infection
by making thin, slippery mucus that traps
pathogens and is moved out of the airways
via cilia, so it can be coughed out of the
lungs. In contrast, CF patients have thick,
sticky mucus that builds up in the airways,
resulting in repeated infections, lung
damage, and respiratory failure. The
disease is caused by mutations in an ion
channel gene called the CF transmem-
brane conductance regulator (CFTR).
These mutations disrupt the ion balance
of the airway lining fluid, leading to
dehydrated mucus. The defective CFTR
also affects other mucus-secreting glands,
notably in the pancreas, as well as sweat
glands.
Current lung treatments for CF patients
include chest pounding and aerobic exer-
cise to loosen the mucus, and medicines to
thin the mucus and limit infection. While
there have been efforts to treat the
underlying cause of the disease with gene
therapy, so far they have not delivered
enough CFTR to the airway lining (or
epithelial) cells to help CF patients in
clinical trials.
In this issue of PLoS Biology, Raymond
Pickles and colleagues report a new gene
therapy approach that increases the deliv-
ery of CFTR to human ciliated airway
epithelial (HAE) cells that are collected
from patients and grown in the laboratory.
This culture model simulates the airway
lining in people and has predicted the
outcomes of other gene therapy approach-
es. The surfaces of cultured HAE cells
from healthy people both produce and
transport mucus, while those from CF
patients retain both the ion channel
dysfunction and dehydrated mucus that
are characteristic of the disease. To
introduce CFTR into HAE cells, the
researchers inserted the gene into human
parainfluenza virus (PIV), which causes
common colds and other respiratory
infections. The researchers had shown in
2005 that PIV targets ciliated HAE cells,
which compose about 70% of the airway
surface lining and normally express CFTR,
making them good candidates for deliver-
ing CFTR to CF patients.
In the current study, PIV with the
CFTR insert (PIVCFTR) infected about
60% of the ciliated CF cells within five
minutes, suggesting that short exposures
might be able to treat CF patients
effectively. To confirm that PIVCFTR
corrected the ion channel dysfunction in
these cells, the researchers stimulated them
with the CFTR activator forskolin. Bio-
electric measurements revealed that the
ion channel activity was restored to
normal levels, which came as a surprise
because mRNA and protein analyses had
shown that the treated cells produced at
least 100 times more CFTR protein than
normal, leading the researchers to expect
an exaggerated jump in ion channel
activity. A possible explanation is that
regardless of CFTR protein levels, cell
membranes can contain only so many of
these ion channels.
PIVCFTR restored airway surface liq-
uid levels in cultures from CF patients to
those of cultures from healthy people.
Untreated ciliated CF cells absorbed so
much liquid that its depth was reduced to
3 mm in 48 hours, while treated cells
maintained liquid depths of about 8 mm,
which is in the normal range. Moreover,
PIVCFTR increased the beat frequency of
CF cilia: untreated cilia beat only about
twice per second, while treated cilia beat at
the normal eight beats per second. These
observations suggest that rehydrating the
mucus is enough to restore effective
beating of the ciliated CF cells that line
airways. Most compellingly, PIVCFTR
also increased mucus transport in ciliated
CF cells, which the researchers measured
by dropping 1-mm fluorescent beads onto
the cultures. The beads did not move at all
on untreated CF cells, while the beads
formed bands indicating that the mucus
moved at about 20 mm per second on
treated cells. However, this is only about
half the normal rate of mucus transport,
which the researchers suggest may be due
to subtle cytotoxic effects of PIV replica-
tion.
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Normal mucus transport is restored in
ciliated airway cultures derived from
patients with cystic fibrosis after re-
placement of the CFTR gene. This image
represents yellow fluorescent beads
embedded in mucus spinning on top
of a culture with bead trails, visualized
by long exposure times. (Beads moved
at 40 mm/sec, approximating mucus ve-
locity in vivo.)
(Image: Raymond J. Pickles).
doi:10.1371/journal.pbio.1000160.g001
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airway lining cells must receive CFTR to
restore mucus hydration and transport in
cultured CF airway cells. Infecting about a
quarter of the cells was enough to restore
normal liquid depths, and infecting about
40% was enough to restore normal mucus
transport. The next step of determining
how many cells must be infected in CF
patients would require testing PIVCFTR
on living organisms. The problem is that
PIV is a human pathogen but most animal
models of CF are in mice, which are not
infected by PIV. Because a newly devel-
oped pig model may not be susceptible to
the virus either, the best test of PIVCFTR
may be on CF patients.
Another drawback to using PIVCFTR
is that infected ciliated cells are shed from
the airway lining within a week, presum-
ably as a natural defense against the virus.
The researchers are hopeful that PIV can
be engineered so it no longer triggers, or at
least delays, this cell shedding, perhaps by
deleting viral envelope glycoproteins that
may be cytotoxic. But because the normal
lifespan of these ciliated cells is just 90–120
days, PIV-based CF treatments would
have to be ongoing in any case. Despite
the hurdles that must be overcome before
PIVCFTR could be used on people, this
study is a welcome advance in the quest
for an effective treatment of this disease
that cuts lives short.
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